Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Capital Expenditures (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Capital Expenditures data on record, last reported at $826000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 566.13% year-over-year to $826000.0; the TTM value through Dec 2025 reached $1.0 million, up 38.99%, while the annual FY2025 figure was $1.0 million, 38.99% up from the prior year.
  • Capital Expenditures reached $826000.0 in Q4 2025 per TNGX's latest filing, up from -$34000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.6 million in Q1 2022 and bottomed at -$1.3 million in Q4 2023.
  • Average Capital Expenditures over 5 years is $190400.0, with a median of $180000.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 3063.64% in 2021, then crashed 465.35% in 2022.
  • A 5-year view of Capital Expenditures shows it stood at $696000.0 in 2021, then crashed by 217.96% to -$821000.0 in 2022, then plummeted by 53.71% to -$1.3 million in 2023, then soared by 109.83% to $124000.0 in 2024, then skyrocketed by 566.13% to $826000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $826000.0 in Q4 2025, -$34000.0 in Q3 2025, and $248000.0 in Q2 2025.